INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.

[1]  Takaaki Ito,et al.  Insulinoma‐associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound‐guided fine‐needle aspiration cytology: An analysis of 14 patients , 2018, Cytopathology : official journal of the British Society for Clinical Cytology.

[2]  Youdinghuan Chen,et al.  INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma , 2018, The American journal of surgical pathology.

[3]  Mark Kriegsmann,et al.  Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56 , 2018, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  Yanqing Wang,et al.  Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. , 2018, Human pathology.

[5]  S. Mukhopadhyay,et al.  Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections , 2018, Modern Pathology.

[6]  J. Bishop,et al.  INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.

[7]  Y. Akagi,et al.  Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor , 2018, Medical Molecular Morphology.

[8]  V. Velcheti,et al.  Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer , 2017, Oncotarget.

[9]  P. Illei,et al.  INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.

[10]  T. Kameya,et al.  A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. , 2017, Gynecologic oncology.

[11]  G. Zamboni,et al.  Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome , 2016, Histopathology.

[12]  G. Zamboni,et al.  Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. , 2016, The oncologist.

[13]  R. Lloyd,et al.  INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. , 2015, American journal of clinical pathology.

[14]  G. Tse,et al.  A Novel Morphologic-Molecular Recurrence Predictive Model Refines Traditional Prognostic Tools for Invasive Breast Carcinoma , 2014, Annals of Surgical Oncology.

[15]  S. Kwon,et al.  Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma , 2014, Histopathology.

[16]  K. Hunt,et al.  Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. , 2011, Human pathology.

[17]  Yun Wu,et al.  Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges , 2011, Histopathology.

[18]  M. Papotti,et al.  Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. , 2010, Seminars in diagnostic pathology.

[19]  T. Imai,et al.  Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients , 2010, Surgery Today.

[20]  M. Breslin,et al.  Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  P. Tan,et al.  The role of immunohistochemistry in the differential diagnosis of breast lesions. , 2009, Pathology.

[22]  G. Dionigi,et al.  Neuroendocrine carcinomas of the breast. , 2008, International journal of surgery.

[23]  E. López-Bonet,et al.  Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. , 2008, Oncology reports.

[24]  W. Hop,et al.  The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. , 2004, Breast.

[25]  R. Lloyd,et al.  Practical Markers Used in the Diagnosis of Endocrine Tumors , 2004, Advances in anatomic pathology.

[26]  D. Huntsman,et al.  Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. , 2003, Human pathology.

[27]  I. Ellis,et al.  Neuroendocrine differentiation and prognosis in breast adenocarcinoma , 2002, Histopathology.

[28]  M. Papotti,et al.  34&bgr;E12 Cytokeratin Immunodetection in the Differential Diagnosis of Neuroendocrine Carcinomas of the Breast , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  M. Papotti,et al.  Expression of the neuroendocrine phenotype in carcinomas of the breast. , 2000, Seminars in diagnostic pathology.

[30]  M. de Silva,et al.  A novel human insulinoma-associated cDNA, IA-1, encodes a protein with "zinc-finger" DNA-binding motifs. , 1992, The Journal of biological chemistry.

[31]  H. Höfler,et al.  Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses. , 1990, The American journal of pathology.